Asymptomatic COVID-19 Adult Outpatients identified as Significant Viable SARS-CoV-2 Shedders

doi:10.21203/rs.3.rs-403751/v1

PDF

Research Article

Asymptomatic COVID-19 Adult Outpatients identified as Significant Viable SARS-CoV-2 Shedders

https://doi.org/10.21203/rs.3.rs-403751/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Differential kinetics of RNA loads and infectious viral levels in the upper respiratory tract between asymptomatic and symptomatic SARS-CoV-2 infected adult outpatients remain unclear limiting recommendations that may guide clinical management, infection control measures and occupational health decisions. In the present investigation, 496 (2.5%) of 17,911 French adult outpatients were positive for an upper respiratory tract SARS-CoV-2 RNA detection by a quantitative RT-PCR assay, of which 180 (36.3%) were COVID-19 asymptomatic. Of these adult asymptomatic viral shedders, 84.4% had mean to high RNA viral loads (Ct values<30) which median value was significantly higher than that observed in symptomatic subjects (P=0.029), and 50.6% were positive by cell culture assays of their upper respiratory tract specimens. Our findings indicate that COVID-19 asymptomatic adult outpatients are significant viable SARS-CoV-2 shedders in their upper respiratory tract playing a major potential role as SARS-CoV-2 transmitters in various epidemiological transmission chains, promoting COVID-19 resurgence in populations.

Infectious Diseases

Pathology

SARS-CoV-2 RNA

COVID-19

adult outpatients

SARS-CoV-2 RT-qPCR

SARS-CoV-2 Infectious shedders

culture assays

In December 2019 a novel Coronavirus, referenced SARS-CoV-2, was identified as the causative agent of a new respiratory illness designated as COVID-19. Despite of the announced containment measures taken by China, COVID-19 quickly became pandemic and was declared as a Global Health Emergency by WHO. The full clinical spectrum of COVID-19 ranges from mild, self-limiting respiratory tract illness to severe progressive pneumonia, acute severe respiratory distress syndrome, multi-organ failure and death ¹. Rapid investigations in basic virology made it possible to obtain the complete sequence of the RNA viral genome and thus to develop specific and sensitive molecular tests for a reliable detection of this new emerging virus in human respiratory samples ². From January 2020 to the present time, the reference biological diagnosis of COVID-19 is based on detection of SARS-CoV-2 RNA genome by RT-qPCR testing of a nasopharyngeal swab ³. Using some of referenced assays the SARS-CoV-2 RNA loads can be quantitatively estimated by threshold cycle (Ct) which values lower than 30 may be associated to infectious virus detectable by cell culture assays in the respiratory tract of symptomatic or asymptomatic carriers ^4,5. To date, differential kinetics of RNA loads and infectious viral levels between asymptomatic and symptomatic SARS-CoV-2 infected adult outpatients remain unclear limiting recommendations about the use of respiratory tract Ct values that may guide clinical management, infection control measures and occupational health decisions ^3,4. In the present study, we assessed the distribution of viral loads estimated by Ct values according to the presence of reported symptoms and to the delay between the respiratory sample and the onset of symptoms in outpatients. Moreover, among identified COVID-19 asymptomatic patients with high viral RNA loads, we investigated the presence of infectious SARS-CoV-2 particles in their upper respiratory tract specimens by cell culture assays.

Following to the first national COVID-19 lockdown occurring from 11 March to 13 May of 2020, France initiated a massive viral screening strategy authorizing any person with or without a medical prescription to perform an RT-qPCR detection test for SARS-CoV-2, resulting in the performance of 720 to 750,000 tests per week on an outpatient basis (French national public health data). From the 4th June to 20th September of 2020 in Champagne-Ardenne area (Norther east of France) we performed a SARS-CoV-2 RT-qPCR assay in trans nasal respiratory samples taken from 17,911 out patients [11,820 women / 6,091 men; mean age (± SD): 41.79 ± 22.52 years (0–99 years)]. For each study patient basic demographic data and reports of COVID-19 symptoms and the time delay between the sampling and the onset of reported symptoms were recovered and registered by a medical pathologist (MD) at the time of the trans-nasal sample. The Institutional Ethics Committee (IEC), University hospital of Reims (Grand-Est, France) waived the requirement of informed consent and approved the study. Our protocols and investigations conformed to the principles outlined in the Declaration of Helsinki for use of human tissue or subjects.

Our quantitative real-time RT-PCR assay was based on the co-detection of two different RNA-dependent RNA polymerase (RdRp) viral gene target sequences (IP2 and IP4 respectively) in trans nasal respiratory samples as described previously ².

Cell culture assays for the detection of infectious SARS-CoV-2 in respiratory specimens were performed using Vero E6 cells according to the CDC protocol ⁶. Briefly, cultured Vero cells were classically infected by 200 µL of pure trans-nasal samples and monitored daily for 4 days to examine the presence cytopathic effects. Following 96 hours of cell culture, we determined the presence of infectious replicative particle in 200 µl of supernatants of cell culture using a referenced RT-PCR assays targeting RdRp gene ⁶. Fold of RNA viral loads increase per ml of cell culture supernatants at 96 hours post-inoculation of cell culture was estimated for each tested respiratory specimen. Fold values greater than 1 were considered as representative of a viral RNA replication activity related to an infection of cultured cells by a viable viral strain for each tested respiratory specimen. Finally, at 96 hours post infection of cultured Vero cells, a classical lysis range titration was performed to determine a viral titer (PFU/mL) for each tested respiratory specimen.

Quantitative variables were all compared using the Mann Whitney U test or two-way ANOVA test and a P-value < 0.05 was considered statistically significant. Data were also represented as standard curve to regression sigmoidal with 95% confidence. All statistical analyses were performed using GraphPad Prism 8 (GraphPad) and SAS version 9.4 (SAS Institute Inc.).

Quantitative cycle threshold (Ct) values of RdRp (RNA dependent RNA polymerase) RNA target sequence (IP4) of SARS-CoV-2 were obtained after serial ten-fold dilutions of synthetic SARS-CoV-2 RNA transcripts ranging from 10⁸ to 10³ copies. These positive controls for used for real-time RT-qPCR were synthetic RNA derived from cDNA plasmid of the BetaCoV_Wuhan_WIV04_2019 strain (EPI_ISL_402124). A significant correlation (R² = 0.995, P < 10^− 4) was displayed between Ct values of IP4 sequence of SARS-CoV-2 and log₁₀ starting quantity of SARS-CoV-2 RNA copies: this curve was used in each RT-qPCR serial analyses to validate our quantitative assay to check that obtained Ct values inversely reflected viral load levels (Fig. 1A).

Among 17,911 study outpatients, 496 (2.8%) patients (298 women /198 men; mean age (± SD), 32.31 ± 17.79 years) were detected positive with low to high viral loads (median (± SD) Ct value of 23.57 ± 6.74) of which 180 (36.3%) were asymptomatic. We identified two distinct subsets of viral load values that were strongly segregated by a cut-off Ct value of 30 in both asymptomatic and symptomatic patients (P < 10^− 4) and this result appeared to be not associated with significant differences in median age levels between these two subgroups (P = 0.85) (Fig. 1B). We found that the proportion of asymptomatic patients with low viral loads was significantly higher than that observed in symptomatic patients (Ct values ≥ 30: 25% versus 11.7%, P = 0.003, Fig. 1B). Remarkably 75% of asymptomatic patients had mean to high viral loads which median value was slightly higher than that observed in symptomatic patients (Ct values < 30: 21.60 ± 0.24 vs. 22.57 ± 0.38; P = 0.029) (Fig. 1B). As expected, viral RNA loads in upper respiratory tract of study outpatients appeared to be well correlated with the time delay between the respiratory sample and the onset symptoms (Fig. 1C). Only the viral loads of patients who were sampled between 8 and 28 days after symptom onset were significantly lower than those of asymptomatic patients (P = 0.041) (Fig. 1D).

Panel A. Cycle threshold (Ct) values of RNA dependent RNA polymerase (RdRp) target sequence (IP4) on SARS-CoV-2 RNA genome after serial ten-fold dilutions of synthetic SARS-CoV-2 RNA transcripts ranging from 10⁸ to 10³ copies. These positive controls for used for real-time RT-qPCR were synthetic RNA derived from cDNA plasmid of the BetaCoV_Wuhan_WIV04_2019 strain (EPI_ISL_402124). A significate correlation (R² = 0.995, P < 10^− 4) was displayed between Ct values of IP4 sequence of SARS-CoV-2 and log₁₀ starting quantity of SARS-CoV-2 RNA copies: this curve was used in each RT-qPCR serial analyses to validate our quantitative assay and to check that obtained Ct values inversely reflected viral load levels. Panel B and D. Boxes denote interquartile ranges, and horizontal bars denote median CT values of IP4 sequence among patients asymptomatic or symptomatic. Whiskers IP4 Ct values denote the maximum and minimum values below or above the median. Panel B. The shaded boxes indicate IP4 Ct values < 30 among asymptomatic (n = 135) or symptomatic (n = 279) patients whereas white boxes indicate IP4 Ct values ≥ 30 among asymptomatic (n = 45) or symptomatic (n = 37) patients (P < 0.0001). Panel C. Correlation of means Ct values in COVID-19 positive patients and days after onset of symptoms. The outer dotted lines are 95% confidence interval. Data represent standard curve to regression sigmoidal with a goodness of fit (R² = 0.997). Panel D. Comparison of IP4 Ct values between asymptomatic outpatients (n = 180) and symptomatic sub-groups of outpatients stratified according to the delay between the respiratory sample and the onset of symptoms; 0–4 (n = 220), 5–7 (n = 73) and 8–28 (n = 23) days after the apparition of clinical symptoms (P < 0.0001). Data represent the median ± SD. *: P < 0.05; according to ANOVA test. Data represent the median ± SD. *: P < 0.05; ****: P < 0.0001; according to ANOVA test.

To investigate whether asymptomatic patients with a mean to high viral load (Ct values < 30) were SARS-CoV-2 infectious shedders, we assessed the existence of a viral genomic RNA replication activity following infection of cultured cells by their upper respiratory tract specimens. Among the 135 asymptomatic patients with RT-PCR Ct values lower than 30, only 83 had frozen stored available samples that were tested by our culture assay protocol. Results were expressed as fold of RNA viral load level increase per ml of cell culture supernatants at 96 hours post-inoculation of Vero cells (Fig. 2). We observed a strong correlation (R² = 0.591, P < 0.0001) between initial SARS-CoV-2 RT-PCR Ct values in respiratory specimens and fold increase of viral RNA levels following viral culture of the same samples (Fig. 2).

Linear regression curve between IP4 Ct values in COVID-19 asymptomatic patients and fold of viral SARS-CoV-2 RNA load level increase after 96 hours viral culture on Vero cells (log10 copies/mL) (R² = 0.591, P < 10^− 4) (n = 83). Fold values greater than 1 were considered as representative of a viral RNA replication activity related to an infection of cultured cells by viable viral particles. Linear regression was performed, and slopes were compared using Spearman test. P values < 0.05 were considered as statistically significant.

This correlation confirmed the reported association between RNA load levels and viral infectivity in upper respiratory tract of COVID-19 patients and demonstrated the reliability of our experimental approach ^7–9. Among studied asymptomatic patients, 50.6% of them were characterized by the presence of viable virus (fold of viral RNA level increase > 1) associated with RT-PCR Ct values lower than 30 in their respiratory specimens, whereas 39.76% of them evidenced no viable viral particles (fold of viral RNA level increase < 1) despite RT-PCR Ct values lower than 30 in their respiratory specimens. None of the asymptomatic patients with RT-PCR Ct values upper than 30 in their upper respiratory tract demonstrated the presence of detectable replicative viral particles (Fig. 2).

Few reports compared upper respiratory tract RNA loads between asymptomatic and symptomatic SARS-CoV-2 infected patients ^4,5. In the present investigation, we remarkably identify major proportions of asymptomatic outpatients with mean to high SARS-CoV-2 RNA loads in upper respiratory tract which median value was slightly higher than that observed in symptomatic outpatients (Fig. 1B). As recently reported in a meta-analysis compelling SARS-CoV-2, SARS-CoV, and MERS-CoV investigations, a viable viral shedding in the upper respiratory tract is present during pre-symptomatic or symptomatic phase with cultivable SARS-CoV-2 titers in the upper respiratory tract that peak in the first week of illness, whereas SARS-CoV-2 RNA shedding in respiratory samples can be prolonged during several weeks ¹⁰. Two recent publications on COVID-19 patients reported no infectious virus detectable by classical cell culture assays when RT-PCR estimated by threshold cycle (Ct) values were more than 30 in the respiratory tract samples ^8,11,12. Taken together, these reports allowed us to firstly evaluate the potential infectiousness of our study COVID-19 outpatient indicating that subjects with median to high RT-PCR assays (Ct values lower than 30) may shed infectious virus in their respiratory tract and therefore may be active viral transmitters ^8,11,13 (Fig. 1).

We observed the highest viral load levels in throat swabs sampled at the time or less than 4 days of symptom onset confirming that infectiousness peaked occurred on or before symptom onset ^12–14. Interestingly, our findings demonstrated that the mean RNA load value measured in asymptomatic outpatients was not statistically different from those detected in patients sampled between 5 to 7 days after the onset of symptoms indicating that they may be equivalent in terms of infectiousness (Fig. 1D). Moreover, as 75% of asymptomatic patients displayed high viral load values in their upper respiratory tract (mean Ct value (± SD) 20.08 ± 2.97) it is possible that an unsuspected part of this patient sub-group may be chronic respiratory tract viral shedders during several weeks and may be defined as COVID-19 super-spreaders (Fig. 1D) ¹⁵.

In previous published reports, there is some evidence that patients may not be infectious for the entire period that they are SARS-CoV-2 positive by RT-PCR assay and that infectivity may be related to the viral load and time since symptom onset ⁸. In the present report, our results compared RNA viral load levels between upper respiratory tract samples taken from symptomatic and asymptomatic SARS-CoV-2 infected adult outpatient subgroups (Fig. 1). In the present investigation, cultured cell isolation of virus was used the referenced method to determine contagiousness of asymptomatic patient because a positive viral RNA detection by RT-PCR did not strictly correlate with the presence of infectious virus in respiratory specimens ^7,9. Based on our cell culture assay results, we can suggest that asymptomatic patients with Ct values equal or above 30 was not an infectious viral particles shedders and thus appeared as being not contagious (Fig. 2). Our findings appear to be fully in agreement with those previously published that demonstrated a relationship of decreasing positive culture proportional to decreasing viral load and inferred that patients with threshold Ct values higher than 28 to 34 were no longer contagious ^4,5,9. Although we are unable to quantify the contributions of asymptomatic patients to transmission of SARS-CoV-2, our results evidenced that asymptomatic patients had the potential for significant infectious viral shedding with viral titers estimated from 10¹ to 10⁶ PFU/mL of respiratory specimens (data not shown). Shedding of high viral titers (> 10³ PFU/mL) in the respiratory tract of COVID-19 asymptomatic patients might result in significant production of infectious droplets and possibly aerosol viral transmission in various epidemiological conditions ^8,9,13.

In conclusions, our SARS-CoV-2 RNA loads measures in upper respiratory tract samples revealed that asymptomatic outpatients shed significant levels of infectious virus in their respiratory tract playing a major role as viral transmitters in various epidemiological transmission chains, promoting COVID-19 resurgence. The impact of asymptomatic viral shedders on COVID-19 epidemic dynamics remains to be assessed in further longitudinal multicenter studies.

Financial support

This work was supported by a research grant URCA-2020-EA4684 dedicated to research teams from the University of Reims Champagne-Ardenne (URCA), France.

Competing interests

The authors declare no-competing interest.

Ethical Approval

The Institutional Ethics Committee (IEC), University hospital of Reims (Grand-Est, France) waived the requirement of informed consent and approved the study. Patients did not provide individual consent because of the retrospective and non-interventional nature of this study, in accordance with French legislation. No patient had previously raised an opposition to the use of their medical records data or the samples collected at the time of diagnosis. Data confidentiality was preserved during this internal study (Reims University Hospital GDPR register number RMR004-061120), and collection of biological specimens was registered in French Ministry of Higher Education and Research as number DC-2020-4052.

Author’s Contributions

L.A and M.G designed the study, analyzed the data and wrote the manuscript; M.G analyzed the data and designed the figure; Y.N’G analyzed the data and performed statistics analyses. A-L.L, L.H and I.M participated to the design of the study.

Zhu, N. et al. Brief Report: A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine 382, 727 (2020).
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25, (2020).
Kim, S. E. et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. Int J Infect Dis 95, 441–443 (2020).
Young, B. E. et al. Viral dynamics and immune correlates of COVID-19 disease severity. Clin Infect Dis (2020) doi:10.1093/cid/ciaa1280.
Bullard, J. et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis (2020) doi:10.1093/cid/ciaa638.
Harcourt, J. et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States - Volume 26, Number 6—June 2020 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2606.200516.
Walsh, K. A. et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect 81, 357–371 (2020).
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
La Scola, B. et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 39, 1059–1061 (2020).
Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe (2020) doi:10.1016/S2666-5247(20)30172-5.
Zou, L. et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 382, 1177–1179 (2020).
Lipsitch, M. et al. Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. Science 300, 1966–1970 (2003).
He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature Medicine 26, 672–675 (2020).
Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).
Cave, E. COVID-19 Super-spreaders: Definitional Quandaries and Implications. Asian Bioeth Rev 1–8 (2020) doi:10.1007/s41649-020-00118-2.

No competing interests reported.

PDF

Editorial decision: Major revision
20 Aug, 2021
Reviews received at journal
19 Aug, 2021
Reviewers agreed at journal
03 Aug, 2021
Reviews received at journal
30 May, 2021
Reviewers agreed at journal
30 May, 2021
Reviewers invited by journal
24 May, 2021
Editor assigned by journal
23 May, 2021
Editor invited by journal
20 Apr, 2021
Submission checks completed at journal
20 Apr, 2021
First submitted to journal
09 Apr, 2021

You are reading this latest preprint version

Asymptomatic COVID-19 Adult Outpatients identified as Significant Viable SARS-CoV-2 Shedders

Status:

Version 1

Abstract

Figures

Introduction

Patients And Methods

Results

Discussion

Declarations

References

Additional Declarations

Status:

Version 1